DOT1L is a novel cancer stem cell target for triple negative breast cancer. Kurani H, Razavipour SF, Harikumar KB, Dunworth M, et al. Clin Cancer Res 2022 Feb 8. pii: 1078-0432.CCR-21-1299.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kurani H, Razavipour SF, Harikumar KB, Dunworth M, et al. DOT1L is a novel cancer stem cell target for triple negative breast cancer. Clin Cancer Res 2022 Feb 8. pii: 1078-0432.CCR-21-1299.
PMID: 35135840